Sorilux

Sorilux is a brand name of calcipotriene topical, approved by the FDA in the following formulation(s):

SORILUX (calcipotriene - aerosol, foam; topical)

• 
  Manufacturer: STIEFEL LABS INC
  
  Approval date: October 6, 2010
  
  Strength(s): 0.005% ^[RLD]

Has a generic version of Sorilux been approved?

No. There is currently no therapeutically equivalent version of Sorilux available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Sorilux. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Sorilux.

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • October 6, 2013 - NEW DOSAGE FORM
  
  

See also...

• Sorilux Consumer Information (Drugs.com)
• Sorilux Topical Advanced Consumer Information (Micromedex)
• Calcipotriene Cream Consumer Information (Wolters Kluwer)
• Calcipotriene Solution Consumer Information (Wolters Kluwer)
• Calcipotriene topical Consumer Information (Cerner Multum)
• Calcipotriene Topical Advanced Consumer Information (Micromedex)
• Calcipotriene AHFS DI Monographs (ASHP)